Experimental Drug for Alzheimer Disease Shows Promise
After six to 12 months of treatment with the drug, patients no longer had amyloid protein plaques.
Alzheimer Disease
FDA Panel Votes on Aducanumab for Alzheimer Disease
The investigational treatment, which is administered as a monthly intravenous infusion, binds to aggregated β-amyloid and promotes removal of amyloid from the brain.
CNS-Active Meds Often Prescribed for Older Adults With Dementia
Overall, Rx filled for antidepressants in 49.8 percent, opioids in 29.8 percent, anxiolytics in 26.8 percent
MPR Weekly Dose Podcast Episode 47
This week we have remdesivir news; A new opioid and spinal muscular atrophy treatments are approved; A sublingual epinephrine treatment; And the latest on Biogen’s investigational Alzheimer disease treatment. Also, we have a brief summary of the other drugs in the pipeline from the past week.
Aducanumab Gets Priority Review for Alzheimer Disease
The FDA has accepted for Priority Review the Biologics License Application for aducanumab (Biogen) for the treatment of Alzheimer disease.
Vaccination Linked to Reduced Alzheimer Disease Risk
At AAIC 2020, 2 presentations separately discussed observing a reduced risk of AD in patients who received the influenza and pneumonia vaccines.
Aducanumab BLA for Alzheimer Disease Submitted for FDA Review
Biogen has submitted its Biologics License Application (BLA) to the Food and Drug Administration (FDA) for aducanumab as a treatment of Alzheimer disease (AD).
First Diagnostic Agent Approved to Image Tau Pathology in Patients Being Evaluated for Alzheimer Disease
Tauvid is indicated for use with positron emission tomography (PET) imaging of the brain.
Investigational Therapies Miss Primary End Point in Autosomal Dominant Alzheimer Disease Trial
Topline data were announced from the phase 2/3 DIAN-TU study of solanezumab (Eli Lilly) and gantenerumab (Genentech) in patients at risk for or with dominantly inherited Alzheimer disease.
Long-Term Systemic Hormone Therapy May Up Alzheimer Risk
Risk increases associated with hormone therapy exposure over 10 years in women <60 years at initiation
